300723SZSE

Announcement on the Acceptance of Clinical Trial Registration Application for Innovative Drug APH04935 Tablets by Wholly-Owned Subsidiary

✨ AI Summary

The announcement informs that the clinical trial application for the innovative drug APH04935 tablets, developed by the wholly-owned subsidiary of Yipinhong Pharmaceutical Group, has been accepted by the National Medical Products Administration. The drug aims to assist in weight loss and long-term weight management for overweight or obese adults. The company emphasizes that this acceptance does not significantly impact its short-term financial status or operational performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

The stock code: 300723
The stock abbreviation: Yipinhong
Announcement number: 2026-030

Yipinhong Pharmaceutical Group Co., Ltd. announces that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received acceptance of the clinical trial application for the innovative drug APH04935 tablets from the National Medical Products Administration, along with the "Acceptance Notice." The relevant details are as follows:

1. Main Content of the Acceptance Notice

Drug NameApplication MatterIndicationAcceptance Number
APH04935 TabletsDomestic production drug registration clinical trialWeight loss and long-term weight management for overweight or obese adultsCXHL2600660, CXHL2600661, CXHL2600662

According to Article 32 of the Administrative Licensing Law of the People's Republic of China, the application has been accepted after review.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.